It marks the corporate’s first fairness funding since its preliminary public providing in 2004.
Biocon issued 136,363,635 fairness shares of face worth Rs 5 every to eligible certified institutional consumers at a difficulty worth of Rs 330 per fairness share (together with a premium of Rs 325 per fairness share), in keeping with an organization assertion.
The QIP, which opened on June 16 and closed on June 19, witnessed strong investor curiosity from a various group of home and worldwide traders, the corporate stated.
“The robust response to our QIP displays deep investor conviction in Biocon’s differentiated technique and constant execution,” stated Siddharth Mittal, CEO and managing director, Biocon. “This capital elevate additional strengthens our steadiness sheet, enabling us to put money into innovation, broaden international entry to lifesaving biopharmaceuticals, and advance our objective of delivering reasonably priced healthcare options that deal with urgent well being inequities worldwide.”
The corporate stated its last order guide was effectively diversified when it comes to investor sort throughout home mutual funds, insurance coverage corporations and international institutional traders.The main traders who participated within the situation included SBI Mutual Fund, ICICI Prudential Mutual Fund, HDFC Life Insurance coverage, Nippon India Mutual Fund, Mirae Asset Mutual Fund, Aditya Birla Mutual Fund, Franklin Templeton, SBI Basic Insurance coverage, Authorities Pension Fund International and Blackrock.The proceeds from the QIP will probably be utilised for buy of excellent optionally convertible debentures issued by the corporate’s subsidiary Biocon Biologics from Goldman Sachs India AIF Scheme – 1 and Goldman Sachs India Different Funding Belief AIF Scheme – 2. The funds may also be used for compensation, pre-payment or redemption of sure excellent monetary devices issued and/or borrowings availed by the corporate, to fulfill different monetary commitments and for normal company functions, stated the assertion.
The post-issue shareholding of the promoter and promoter group stands at 54.45%.
Kotak Mahindra Capital, BofA India Securities and Goldman Sachs (India) Securities acted as guide working lead managers to the QIP.
